Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Revenue (2016 - 2025)

Historic Revenue for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $4.7 billion.

  • Teva Pharmaceutical Industries' Revenue rose 1139.75% to $4.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $17.3 billion, marking a year-over-year increase of 431.58%. This contributed to the annual value of $17.3 billion for FY2025, which is 431.58% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Revenue stood at $4.7 billion, which was up 1139.75% from $4.5 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Revenue's 5-year high stood at $4.7 billion during Q4 2025, with a 5-year trough of $3.6 billion in Q3 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Revenue value was $3.9 billion (recorded in 2021), while the average stood at $4.0 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Revenue tumbled by 860.68% in 2021, and later skyrocketed by 1475.28% in 2023.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Revenue stood at $4.1 billion in 2021, then decreased by 5.27% to $3.9 billion in 2022, then rose by 14.75% to $4.5 billion in 2023, then dropped by 5.12% to $4.2 billion in 2024, then grew by 11.4% to $4.7 billion in 2025.
  • Its last three reported values are $4.7 billion in Q4 2025, $4.5 billion for Q3 2025, and $4.2 billion during Q2 2025.